Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.49 is 325% above its 5-year average of -0.22, near the high end of its 5-year range (-12.77–4.31).
As of the fiscal period ended Tuesday, June 30, 2026. 35.43% above its 12-month average of 0.36.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.49.
DEBT TO EQUITY RATIO
0.49
DEBT TO EQUITY RATIO AVG TTM
0.36
DEBT TO EQUITY RATIO AVG 3Y
-0.27
DEBT TO EQUITY RATIO AVG 5Y
-0.22
DEBT TO EQUITY RATIO AVG 10Y
-0.60
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+35.43%
CURRENT VS 3Y AVG
+279.09%
CURRENT VS 5Y AVG
+324.60%
CURRENT VS 10Y AVG
+181.31%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12
median of 647 covered companies
CURRENT VS SECTOR MEDIAN
+305.82%
vs the sector median at left
Market Cap
$17.36M
Debt to Equity Ratio
0.77
TTM Avg
0.78
3Y Avg
0.55
5Y Avg
1.68
Market Cap
$17.13M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.10
5Y Avg
0.18
Market Cap
$16.73M
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.04
Market Cap
$16.70M
Debt to Equity Ratio
0.21
TTM Avg
0.47
3Y Avg
0.45
5Y Avg
0.39
Market Cap
$16.49M
Debt to Equity Ratio
N/A
TTM Avg
3.08
3Y Avg
1.54
5Y Avg
1.03
Market Cap
$18.40M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$18.54M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.27M | 0.49 | 0.36 | -0.27 | -0.22 |
| Cosmos Health Inc. (COSM)vs › | $17.36M | 0.77 | 0.78 | 0.55 | 1.68 |
| Lipocine Inc. (LPCN)vs › | $17.15M | 0.00 | 0.01 | 0.01 | 0.07 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.13M | 0.00 | 0.00 | 0.10 | 0.18 |
| Palatin Technologies, Inc. (PTN)vs › | $16.73M | 0.03 | 0.03 | 0.03 | 0.04 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.70M | 0.21 | 0.47 | 0.45 | 0.39 |
| Dyadic International, Inc. (DYAI)vs › | $16.49M | N/A | 3.08 | 1.54 | 1.03 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.40M | N/A | 0.00 | 0.02 | 0.01 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.54M | 0.00 | 0.01 | 0.02 | 0.02 |
| BioCardia, Inc. (BCDA)vs › | $16.00M | 0.11 | 0.86 | 0.69 | 0.45 |
Debt/Equity
0.49
Current Ratio
1.19
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.49 |
| 2026-03-31 | 0.43 |
| 2025-12-31 | 0.39 |
| 2025-09-30 | 0.26 |
| 2025-06-30 | 0.23 |
| 2025-03-31 | 0.20 |
| 2024-12-31 | -12.77 |
| 2024-09-30 | -7.17 |
| 2024-06-30 | -0.68 |
| 2024-03-31 | -0.72 |
| 2023-12-31 | -0.91 |
| 2023-09-30 | -1.15 |
| 2023-06-30 | -1.53 |
| 2023-03-31 | -2.24 |
| 2022-12-31 | -3.78 |
| 2022-09-30 | 4.31 |
| 2022-06-30 | 1.48 |
| 2022-03-31 | 0.06 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.01 |
| 2020-12-31 | 7.89 |
| 2020-09-30 | -1.59 |
| 2020-06-30 | -1.46 |
| 2020-03-31 | -1.38 |
| 2019-12-31 | -2.13 |
| 2019-09-30 | -2.37 |
| 2019-06-30 | -4.42 |
| 2019-03-31 | -1.52 |
| 2018-12-31 | -3.41 |
| 2018-09-30 | 0.89 |
| 2018-06-30 | 0.42 |
| 2018-03-31 | 9.08 |
| 2017-12-31 | -0.68 |
| 2017-09-30 | -0.27 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
